NASDAQ:CTKB Cytek Biosciences - CTKB Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $8.75 -0.05 (-0.57%) (As of 03/23/2023 12:00 AM ET) Add Compare Share Share Today's Range$8.72▼$9.0350-Day Range$8.75▼$13.4752-Week Range$7.38▼$16.05Volume726,365 shsAverage Volume709,617 shsMarket Capitalization$1.19 billionP/E Ratio437.72Dividend YieldN/APrice Target$14.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Cytek Biosciences MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside63.8% Upside$14.33 Price TargetShort InterestBearish5.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.51Based on 3 Articles This WeekInsider TradingSelling Shares$1.40 M Sold Last QuarterProj. Earnings Growth133.33%From $0.12 to $0.28 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.01 out of 5 starsMedical Sector652nd out of 989 stocksAnalytical Instruments Industry21st out of 28 stocks 3.3 Analyst's Opinion Consensus RatingCytek Biosciences has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.33, Cytek Biosciences has a forecasted upside of 63.8% from its current price of $8.75.Amount of Analyst CoverageCytek Biosciences has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.29% of the float of Cytek Biosciences has been sold short.Short Interest Ratio / Days to CoverCytek Biosciences has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Cytek Biosciences has recently increased by 4.37%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCytek Biosciences does not currently pay a dividend.Dividend GrowthCytek Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CTKB. Previous Next 0.8 News and Social Media Coverage News SentimentCytek Biosciences has a news sentiment score of -0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cytek Biosciences this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Cytek Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytek Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,404,548.00 in company stock.Percentage Held by Insiders15.90% of the stock of Cytek Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions49.48% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Cytek Biosciences are expected to grow by 133.33% in the coming year, from $0.12 to $0.28 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytek Biosciences is 437.72, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 136.18.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytek Biosciences is 437.72, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 154.13.Price to Book Value per Share RatioCytek Biosciences has a P/B Ratio of 2.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cytek Biosciences (NASDAQ:CTKB) StockCytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.Read More Receive CTKB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CTKB Stock News HeadlinesMarch 24, 2023 | americanbankingnews.comCytek Biosciences (NASDAQ:CTKB) Shares Down 4.1% on Insider SellingMarch 23, 2023 | finance.yahoo.comCytek Biosciences, Inc.'s (NASDAQ:CTKB) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measuresMarch 24, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 23, 2023 | americanbankingnews.comCytek Biosciences, Inc. (NASDAQ:CTKB) CTO Ming Yan Sells 20,000 SharesMarch 7, 2023 | benzinga.comCytek® Biosciences Introduces New 20-Color AML PanelMarch 7, 2023 | finance.yahoo.comCytek® Biosciences Introduces New 20-Color AML PanelMarch 1, 2023 | finance.yahoo.comCytek Biosciences, Inc. (CTKB) Q4 Earnings Top EstimatesFebruary 28, 2023 | msn.comCytek Biosciences GAAP EPS of $0.02, revenue of $164.04MMarch 24, 2023 | Weiss Ratings (Ad)Banking NightmareDuring and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …February 28, 2023 | finance.yahoo.comCytek Biosciences Reports Fourth Quarter and Full Year 2022 Financial ResultsFebruary 28, 2023 | finance.yahoo.comSale of Flow Cytometry and Imaging Business From DiaSorin to Cytek® Biosciences CompletedFebruary 22, 2023 | seekingalpha.comCTKB Cytek Biosciences, Inc.February 15, 2023 | marketwatch.comCytek Biosciences Down 11% on $46.5M Acquisition PlansFebruary 14, 2023 | msn.comCytek Biosciences Acquires Flow Cytometry & Imaging Business From DiaSorinFebruary 13, 2023 | msn.comCytek Biosciences to acquire flow cytometry & imaging business from DiaSorinFebruary 7, 2023 | finance.yahoo.comCytek Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023February 6, 2023 | finance.yahoo.comCytek Biosciences to Participate in Upcoming Investor ConferencesDecember 30, 2022 | finance.yahoo.comCytek Biosciences (NASDAQ:CTKB) shareholders have endured a 37% loss from investing in the stock a year agoDecember 19, 2022 | finance.yahoo.comShould You Invest in Cytek Biosciences (CTKB) for a Long-Term?December 15, 2022 | msn.comCytek Biosciences Earnings Perspective: Return On Capital EmployedNovember 21, 2022 | finance.yahoo.comCytek Biosciences to Participate in the Piper Sandler Healthcare ConferenceNovember 15, 2022 | finance.yahoo.comCytek® Biosciences Introduces Cytek CloudNovember 12, 2022 | seekingalpha.comCytek Biosciences, Inc. (CTKB) Q3 2022 Earnings Call TranscriptNovember 11, 2022 | finance.yahoo.comCytek Biosciences Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 9, 2022 | finance.yahoo.comCytek Biosciences, Inc. (CTKB) Q3 Earnings Surpass EstimatesNovember 9, 2022 | seekingalpha.comCytek Biosciences reports mixed Q3 earnings; reaffirms FY22 guidanceNovember 9, 2022 | finance.yahoo.comCytek Biosciences Reports Third Quarter 2022 Financial ResultsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CTKB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CTKB Company Calendar Last Earnings8/10/2022Today3/23/2023Next Earnings (Estimated)5/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTKB CUSIPN/A CIK1831915 Webwww.cytekdev.com Phone877-922-9835FaxN/AEmployees496Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.33 High Stock Price Forecast$15.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+63.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.02 Trailing P/E Ratio437.72 Forward P/E Ratio72.92 P/E GrowthN/ANet Income$2.58 million Net Margins1.69% Pretax Margin0.77% Return on Equity0.98% Return on Assets0.81% Debt Debt-to-Equity Ratio0.01 Current Ratio9.26 Quick Ratio8.28 Sales & Book Value Annual Sales$164.04 million Price / Sales7.22 Cash Flow$0.07 per share Price / Cash Flow126.88 Book Value$3.16 per share Price / Book2.77Miscellaneous Outstanding Shares135,430,000Free Float113,897,000Market Cap$1.19 billion OptionableNot Optionable Beta0.30 Key ExecutivesDr. Wenbin Jiang Ph.D. (Age 59)Pres, CEO & Chairman Comp: $568.5kMr. Patrik Sebastian Jeanmonod (Age 57)Chief Financial Officer Comp: $412.54kDr. Ming Yan Ph.D. (Age 60)CTO & Director Comp: $514.78kDr. Allen B. Poirson Ph.D. (Age 63)Sr. VP of Bus. & Corp. Devel. Mr. Chris WilliamsChief Operating OfficerMr. Mark EdingerVP of Scientific AffairsMr. Paul D. GoodsonHead of Investor RelationsMs. Valerie T. Barnett J.D. (Age 48)Gen. Counsel & Corp. Sec. Ms. Connie WedelChief People OfficerMr. Todd GarlandChief Commercial OfficerMore ExecutivesKey CompetitorsQuanterixNASDAQ:QTRXBionano GenomicsNASDAQ:BNGONautilus BiotechnologyNASDAQ:NAUTCue HealthNASDAQ:HLTHAkoya BiosciencesNASDAQ:AKYAView All CompetitorsInsiders & InstitutionsMing YanSold 20,000 sharesTotal: $185,800.00 ($9.29/share)Wenbin JiangSold 20,000 sharesTotal: $202,600.00 ($10.13/share)Voya Investment Management LLCBought 28,550 shares on 2/28/2023Ownership: 0.119%Ming YanSold 20,000 sharesTotal: $218,800.00 ($10.94/share)Macquarie Group Ltd.Bought 1,052,736 shares on 2/21/2023Ownership: 0.781%View All Insider TransactionsView All Institutional Transactions CTKB Stock - Frequently Asked Questions Should I buy or sell Cytek Biosciences stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytek Biosciences in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CTKB shares. View CTKB analyst ratings or view top-rated stocks. What is Cytek Biosciences' stock price forecast for 2023? 3 brokers have issued 12 month price targets for Cytek Biosciences' stock. Their CTKB share price forecasts range from $14.00 to $15.00. On average, they predict the company's share price to reach $14.33 in the next year. This suggests a possible upside of 63.8% from the stock's current price. View analysts price targets for CTKB or view top-rated stocks among Wall Street analysts. How have CTKB shares performed in 2023? Cytek Biosciences' stock was trading at $10.21 at the beginning of 2023. Since then, CTKB stock has decreased by 14.3% and is now trading at $8.75. View the best growth stocks for 2023 here. When is Cytek Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023. View our CTKB earnings forecast. How were Cytek Biosciences' earnings last quarter? Cytek Biosciences, Inc. (NASDAQ:CTKB) announced its quarterly earnings results on Wednesday, August, 10th. The company reported $0.03 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.01. The company had revenue of $40.16 million for the quarter, compared to analyst estimates of $41.34 million. Cytek Biosciences had a net margin of 1.69% and a trailing twelve-month return on equity of 0.98%. What ETFs hold Cytek Biosciences' stock? ETFs with the largest weight of Cytek Biosciences (NASDAQ:CTKB) stock in their portfolio include First Trust Innovation Leaders ETF (ILDR), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), BlackRock Future Health ETF (BMED), Principal Healthcare Innovators ETF (BTEC), Invesco Dynamic Market ETF (PWC), iShares Biotechnology ETF (IBB). What guidance has Cytek Biosciences issued on next quarter's earnings? Cytek Biosciences issued an update on its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $225.00 million-$235.00 million, compared to the consensus revenue estimate of $214.66 million. When did Cytek Biosciences IPO? (CTKB) raised $248 million in an initial public offering (IPO) on Friday, July 23rd 2021. The company issued 14,564,635 shares at $16.00-$18.00 per share. What is Cytek Biosciences' stock symbol? Cytek Biosciences trades on the NASDAQ under the ticker symbol "CTKB." Who are Cytek Biosciences' major shareholders? Cytek Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (1.32%), Macquarie Group Ltd. (0.78%), New York State Common Retirement Fund (0.61%), Point72 Asset Management L.P. (0.60%), Miura Global Management LLC (0.58%) and Charles Schwab Investment Management Inc. (0.50%). Insiders that own company stock include Jack Ball, Ming Yan, Patrik Jeanmonod, Ra Capital Management, LP and Wenbin Jiang. View institutional ownership trends. How do I buy shares of Cytek Biosciences? Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cytek Biosciences' stock price today? One share of CTKB stock can currently be purchased for approximately $8.75. How much money does Cytek Biosciences make? Cytek Biosciences (NASDAQ:CTKB) has a market capitalization of $1.19 billion and generates $164.04 million in revenue each year. The company earns $2.58 million in net income (profit) each year or $0.02 on an earnings per share basis. How many employees does Cytek Biosciences have? The company employs 496 workers across the globe. How can I contact Cytek Biosciences? The official website for the company is www.cytekdev.com. The company can be reached via phone at 877-922-9835 or via email at investors@cytekbio.com. This page (NASDAQ:CTKB) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.